Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... China, Aug. 18 /PRNewswire-FirstCall/,-- MicuRx Pharmaceuticals, ... antibiotics, today announced the nomination of,MRX- ... candidate. MRX-I is an,antibacterial molecule targeting ... aureus (MRSA).,Simultaneously, the company expanded its ...
... Drug Target Knowledge Databases ... Related to Nuclear Receptors and Proteases, PARIS, August ... solutions that accelerate life sciences discovery,announced today the release ... include knowledge databases for the important,drug targets Nuclear Receptor ...
... Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ... of China,("PRC"), today announced financial results for the quarter and ... Highlights -- Total revenues increased to $19.4 million, up ... 2007 -- Gross profit was $9.7 million, up 76.4% ...
Cached Biology Technology:MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China 2Aureus Pharma Releases New Unified Knowledge Database 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/18/2014)... In a sample of patients with undiagnosed, suspected genetic ... associated with a higher molecular diagnostic yield than traditional ... JAMA . The study is being released to ... meeting. , Exome sequencing, which sequences the protein­coding region ... genetic material present in a cell or organism), has ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
ANTI PIG LDH H4...
... in refrigerators, freezers, or liquid nitrogen. Conveniently sized to ... color coding to project, user, lab, etc. Holes in ... air circulation. Supplied with 10 x 10 (11.6 mm ... dimensions: 13 x 13 x 5.1 cm H (5 ...
Recombinant Rhesus Monkey IFN-Alpha...
RABBIT ANTI AMPHOTERIN...
Biology Products: